What is the step‑by‑step protocol for weaning a patient from Airway Pressure Release Ventilation (APRV) mode?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Weaning from APRV: Step-by-Step Protocol

The optimal approach to weaning from APRV involves a systematic reduction of P-high while gradually increasing T-high until the patient reaches CPAP-equivalent settings (P-high ≤10 cmH₂O, T-high ≥10 seconds, FiO₂ ≤0.4), at which point transition to spontaneous breathing trials and extubation should follow established ventilator liberation protocols. 1

Initial APRV Settings (For Context)

Before discussing weaning, understand that optimal APRV settings using the Time-Controlled Adaptive Ventilation (TCAV) method include:

  • P-high: Set to plateau pressure (from volume control) or peak inspiratory pressure (from pressure control)
  • T-high: Match the respiratory rate on conventional ventilation (typically 4-6 seconds)
  • P-low: 0 cmH₂O
  • T-low: Calculated using Peak Expiratory Flow × 75% = Termination of Expiratory Flow (typically 0.4-0.8 seconds) 1

Step-by-Step Weaning Protocol

Step 1: Assess Readiness for Weaning

Begin weaning when the patient demonstrates:

  • Improved oxygenation (stable SpO₂ on lower FiO₂)
  • Resolving underlying pathology
  • Hemodynamic stability
  • Adequate spontaneous breathing effort

Step 2: Reduce P-high Gradually

  • Decrease P-high by 2-3 cmH₂O increments every 4-6 hours as tolerated
  • Target: P-high ≤10 cmH₂O 1
  • Monitor for adequate tidal volumes (4-6 mL/kg during release phase is acceptable) 2
  • Maximum P-high should not exceed 35 cmH₂O during any phase 2

Step 3: Increase T-high Progressively

  • Gradually increase T-high to allow more time for spontaneous breathing
  • Target: T-high ≥10 seconds 1
  • This extends the CPAP phase and reduces the frequency of pressure releases
  • Adjust based on patient comfort and gas exchange

Step 4: Titrate FiO₂ Downward

  • Reduce FiO₂ by 5% increments as oxygenation permits 3
  • Target: FiO₂ ≤0.4 (40%) 1

Step 5: Maintain P-low and T-low Settings

  • Keep P-low at 0 cmH₂O throughout weaning 1
  • Continuously adjust T-low based on expiratory flow analysis (75% of peak expiratory flow termination) 1, 4
  • This personalized, adaptive approach prevents alveolar collapse during the release phase

Step 6: Transition to CPAP

When the patient achieves all three criteria:

  • P-high ≤10 cmH₂O
  • T-high ≥10 seconds
  • FiO₂ ≤0.4

Switch to CPAP mode 1

Step 7: Conduct Spontaneous Breathing Trial (SBT)

Once on CPAP and stable, follow established liberation protocols:

  • Perform SBT with inspiratory pressure augmentation (5-8 cmH₂O pressure support) rather than T-piece 5
  • Duration: 30 minutes to 2 hours
  • This approach increases successful SBT rates (84.6% vs 76.7% without pressure support) 5

Step 8: Extubation Strategy

  • For high-risk patients (hypercapnia, COPD, CHF, or serious comorbidities): Extubate directly to preventive noninvasive ventilation (NIV) immediately after successful SBT 5
  • For standard-risk patients: Extubate to supplemental oxygen

Critical Pitfalls to Avoid

Do NOT use an in-line oscillatory device during APRV weaning - this abolishes the beneficial antegrade secretion clearance mechanism inherent to APRV-TCAV 6

Do NOT reduce P-low below 0 cmH₂O - maintaining zero P-low is essential for the lung-protective mechanism 1

Do NOT use fixed T-low settings - T-low must be continuously recalculated based on expiratory flow to adapt to changing lung mechanics 1, 4

Do NOT rush the weaning process - APRV works by gradually recruiting collapsed lung tissue over hours to days; premature weaning risks re-collapse 7, 4

Protocol Implementation Considerations

The evidence shows significant knowledge gaps among physicians regarding APRV management, with lack of training being the most common barrier (77.9%) 2. Use of a standardized, nurse-driven protocol improves compliance (76%) and acceptance 3. The weaning process typically takes 11 days (median) in patients with acute respiratory failure 3.

Implement ventilator liberation protocols - these reduce mechanical ventilation duration by 25 hours and ICU length of stay by 1 day compared to physician judgment alone 8. While the guidelines don't specify APRV-specific protocols, the principles of protocolized weaning apply universally.

Monitoring During Weaning

Assess every 3-4 hours:

  • Respiratory rate and work of breathing
  • Tidal volumes during release phase
  • Oxygenation (SpO₂, PaO₂/FiO₂ ratio)
  • Hemodynamic stability
  • Patient comfort and synchrony

If deterioration occurs at any step, return to previous stable settings and reassess readiness before attempting further weaning.

References

Related Questions

What should be the APRV (Airway Pressure Release Ventilation) settings on the ventilator for a 57‑year‑old female with ARDS, weight 50 kg, height 156 cm, and a plateau pressure of 27 cm H₂O?
When should Airway Pressure Release Ventilation (APRV) be used instead of Pressure Regulated Volume Control (PRVC), and what are the recommended ventilator settings for each mode?
Can Airway Pressure Release Ventilation (APRV) be used for weaning in a spontaneously breathing patient?
How do I adjust Airway Pressure Release Ventilation (APRV) settings for a patient?
What is the current status of airway pressure release ventilation (APRV) in clinical practice?
What is the recommended treatment approach for rejection‑sensitive dysphoria (RSD) in a patient with attention‑deficit/hyperactivity disorder (ADHD)?
Can an adult patient without severe liver disease, without a history of severe respiratory compromise, and not taking other CNS depressants be started on hydroxyzine while continuing clonazepam (Klonopin)?
What is the prognosis and recommended management for papillary thyroid carcinoma in an adult, including indications for lobectomy versus total thyroidectomy, radioactive iodine therapy, levothyroxine suppression, follow‑up schedule, and treatment of recurrent or metastatic disease?
Is it considered unethical to split a dose of Mounjaro (tirzepatide)?
How should I manage a patient with hyperkalemia (potassium 5.8 mEq/L) and hypocalcemia (calcium 5.8 mg/dL)?
What is the recommended evaluation and management for short‑coupled premature ventricular complexes (PVCs)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.